Results of this pooled analysis indicate that tapentadol extended release (ER) is effective and well tolerated for the management of neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults.

Tapentadol ER is associated with improvements in measures of health-related quality of life in patients with painful DPN.

Tapentadol ER provides consistent efficacy across different patient subgroups divided by age, sex, race, opioid experience and pain intensity.